Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
| ▸ | NCF1 | P14598 | 2/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27490517 | 0.89 | HTR2C (0.41) | HTR2CKDM4EALDH1A1HRH3PLD1 | |
| SCHEMBL27869303 | 0.85 | — | — | |
| SCHEMBL5313919 | 0.81 | CHKA (0.37) | KDM4EALDH1A1 | |
| SCHEMBL1231525 | 0.79 | ALDH1A1 (0.36) | KDM4EALDH1A1 | |
| SCHEMBL4025127 | 0.78 | PIK3CA (0.40) | KDM4E | |
| SCHEMBL27961232 | 0.76 | HRH4 (0.43) | ALDH1A1HRH3 | |
| SCHEMBL6032448 | 0.76 | HTR2C (0.44) | HTR2CKDM4EALDH1A1HRH3PLD1 | |
| SCHEMBL6423951 | 0.73 | HTR2C (0.32) | HTR2C | |
| SCHEMBL29364554 | 0.73 | ACHE (0.37) | KDM4EALDH1A1 | |
| SCHEMBL22645263 | 0.72 | ALDH1A1 (0.36) | ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100522955-C | Cytotoxic agents containing novel potent taxanes and their therapeutic use | IMMUNOGEN INC (US) | 2009-08-05 | — | — | CN | claimed |
| CN-100410250-C | Novel spiroheterocyclic compoundsus reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMA (US) | 2008-08-13 | — | — | CN | claimed |
| CN-1384830-A | Novel spiroheterocyclic compounds as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMA (US) | 2002-12-11 | — | — | CN | claimed |
| US-20250066346-A1 | SOLID FORMS OF A BENZTHIAZOLE-PIPERAZINYL-OXAZOLE COMPOUND AND METHODS OF USE THEREOF | HEPAGENE THERAPEUTICS HK LTD (CN) | 2025-02-27 | — | — | US | disclosed |
| CN-118742306-A | Solid forms of benzothiazole-piperazinyl-oxazole compounds and methods of use thereof | 和博医药有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118742306-A | Solid forms of benzothiazole-piperazinyl-oxazole compounds and methods of use thereof | 和博医药有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2023137135-A1 | SOLID FORMS OF A BENZTHIAZOLE-PIPERAZINYL-OXAZOLE COMPOUND AND METHODS OF USE THEREOF | Hepagene Therapeutics (HK) Limited (CN) | 2023-07-20 | — | — | WO | disclosed |
| US-10711000-B2 | Autotaxin inhibitors and uses thereof | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2019228403-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2019-12-05 | — | — | WO | disclosed |
| CN-108886104-A | Phenanthroquinazoline core compounds | 陶氏环球技术有限责任公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108239098-A | Ben Bing Evil Qin oxazolidinone compounds containing tetrahydropyridine and its preparation method and application | 中国医学科学院药物研究所 | 2018-07-03 | — | — | CN | disclosed |
| CN-1384830-A | Novel spiroheterocyclic compounds as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMA (US) | 2002-12-11 | — | — | CN | disclosed |
| CN-1351497-A | Aminopyrimidines as sorbitol dehydrogenase inhibitors | PFIZER PROD INC (US) | 2002-05-29 | — | — | CN | disclosed |
| CN-1340054-A | 2-amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-03-13 | — | — | CN | disclosed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | disclosed |
| EP-1153024-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049018-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
| US-6090825-A | Oxazole derivatives as antagonists of alpha 1C andrenergic receptors | GLAXO WELLCOME INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0793658-A1 | OXAZOLE DERIVATIVES AS ANTAGONISTS OF ALPHA-1C ADRENERGIC RECEPTORS | GLAXO WELLCOME INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016049-A1 | OXAZOLE DERIVATIVES AS ANTAGONISTS OF α-1C ADRENERGIC RECEPTORS | GLAXO WELLCOME INC. (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | CDK14, CDK1, CCNB1 | HTR2C 3417/4885KDM4E 2530/4885ALDH1A1 4801/4885 |
| US-10711000-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | HTR2C 4686/4885KDM4E 4245/4885ALDH1A1 4716/4885 |
| US-20250066346-A1 | SOLID FORMS OF A BENZTHIAZOLE-PIPERAZINYL-OXAZOLE COMPOUND AND METHODS OF USE THEREOF | FXR1, SLC10A1, NR1H4 | HTR2C 3036/4885KDM4E 1135/4885ALDH1A1 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.